JPMorgan analyst Chris Schott added Bristol Myers (BMY) to the firm’s Analyst Focus List as a value idea and keeps an Overweight rating on the shares with a $70 price target Bristol is in the midst of a major new launch, Cobenfy in schizophrenia, with a much-improved long-term competitive environment, the analyst tells investors in a research note. The firm also believes the company is gaining momentum in its new launch portfolio, has its Inflation Reduction Act price negotiation exposure behind it, and continues to trade at a steep discount to peers. As such, JPMorgan sees further room for multiple expansion and upside to 2029 Street estimates, driven by a potentially faster-than-expected Cobenfy launch and improving performance from Bristol Myers’ new product portfolio.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Cytokinetics price target raised to $82 from $80 at RBC Capital
- Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz
- Netflix, MongoDB downgraded: Wall Street’s top analyst calls
- Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline
- Bristol Myers upgraded to Buy from Hold at Jefferies